Search Results
Apr 29, 2026, 10:15 ET A Supply Crisis Is Brewing in the Metals That Power Everything
GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF), Almonty Industries (NASDAQ: ALM) (TSX: AII), Idaho Strategic Resources (NYSE-A: IDR), Brixton Metals (TSXV: BBB) (OTCQX: BBBXF), and Kingfisher Metals (TSXV: KFR) (OTCQB: KGFMF).
More news about: USA News Group
Apr 28, 2026, 07:30 ET Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's
More news about: SOLIGENIX, INC.
Apr 13, 2026, 06:18 ET CALIFORNIA FEDERAL COURT DELIVERS LANDMARK VICTORY FOR HEALTHCARE PROVIDERS IN NO SURPRISES ACT DISPUTE
Officer for HaloMD. "Their strategy backfired completely."Court Affirms Finality of the IDR ProcessAt the heart of the ruling is a powerful affirmation of Congressional intent: the NSA's IDR process was designed to be the final mechanism for resolving surprise billing disputes, not a
More news about: HaloMD
Apr 02, 2026, 07:30 ET Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's
More news about: SOLIGENIX, INC.
Mar 31, 2026, 09:57 ET Rayakan Paskah di The Ritz-Carlton, Bali
destinasi ideal untuk perayaan liburan di pesisir pantai."Easter Brunch di The Ritz-Carlton, Bali tersedia hari, Minggu 5 April 2026, dengan harga IDR 1,500,000++ per orang di The Beach Grill. Anak-anak berusia 3 tahun ke bawah dapat bersantap gratis, dan anak-anak berusia antara 4 dan 12 tahun mendapatkan
More news about: The Ritz-Carlton, Bali
Mar 31, 2026, 07:30 ET Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's
More news about: SOLIGENIX, INC.
Mar 26, 2026, 07:30 ET Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
SGX942 (oral mucositis), is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection
More news about: SOLIGENIX, INC.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's
More news about: Soligenix
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutex Health, Inc. - NUTX
2025 due in part to a "one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process." On this news, Nutex's stock price fell $15.06 per share, or 14.3%, to close at $90.28 per share on March 6, 2026.Pomerantz LLP,
More news about: Pomerantz LLP
Mar 19, 2026, 07:30 ET Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's
More news about: SOLIGENIX, INC.
Mar 18, 2026, 11:22 ET Study Estimates Fintech Lending AdaKami Contributes Up to USD 649 Million to Indonesia's GDP
FEB UI) finds AdaKami, a fintech lending platform licensed and supervised by the Financial Services Authority (OJK), contributed between IDR 6.95 – 10.96 trillion (USD 411 – 649 million) to Indonesia's Gross Domestic Product (GDP) in 2024 through the multiplier effect of its loan
More news about: AdaKami
Mar 12, 2026, 18:50 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutex Health, Inc. - NUTX
2025 due in part to a "one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process." On this news, Nutex's stock price fell $15.06 per share, or 14.3%, to close at $90.28 per share on March 6, 2026.Pomerantz LLP,
More news about: Pomerantz LLP
Mar 12, 2026, 08:17 ET New Audit by The Phia Group Flags Provider Billing Strategies Driving Employer Plan Waste Under the No Surprises Act (NSA)
based on relative billing ratios and IDR offer levels. Providers were classified as: Category 1=relatively low billing ratio, low end of IDR offers; Category 2=relatively high billing ratio, low end of IDR offers; Category 3=relatively high billing ratio, high end of IDR offers; and Category 4=relatively
More news about: The Phia Group, LLC
Mar 10, 2026, 09:17 ET VLS Environmental Solutions Bolsters West Coast Expansion with the Acquisition of IDR Environmental Services
accomplished independently and even more excited about what we will achieve together. We are thrilled to welcome the IDR team to the VLS family." "This is an exciting opportunity for IDR Environmental Services to join VLS and strengthen its logistical and waste processing network," said Dawn DeVroom,
More news about: VLS Environmental Solutions
Mar 10, 2026, 07:30 ET Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
SGX942 (oral mucositis), is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection
More news about: SOLIGENIX, INC.
Mar 05, 2026, 18:33 ET NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM
both higher acuity claims as well as success through the Independent Dispute Resolution ("IDR") process.Regarding arbitration-related revenue: we have submitted between 50-60% of our claims through the IDR process. When an award determination is made, we currently prevail in over 85% of those
More news about: Nutex Health, Inc.
Mar 03, 2026, 15:02 ET Indonesia Promotes #GoBeyondOrdinary at ITB Berlin 2026
participation at ITB Berlin 2026, the Ministry of Tourism targets 498.000 - 541.000 potential tourist transactions (pax), equivalent to approximately IDR 12.9– 14.3 trillion in potential foreign-exchange earnings. This target reflects optimism regarding tourism's growing contribution to national economic
More news about: Ministry of Tourism of the Republic of Indonesia
Feb 26, 2026, 07:30 ET Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
SGX942 (oral mucositis), is an innate defense regulator (IDR), a new class of short, synthetic peptides. It has a novel mechanism of action whereby it modulates the body's reaction to both injury and infection
More news about: SOLIGENIX, INC.
Feb 24, 2026, 07:30 ET Soligenix to Present at BIO Investment & Growth Summit
programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's
More news about: SOLIGENIX, INC.
Feb 05, 2026, 11:44 ET FIS completa con éxito la emisión de bonos por valor de 770 millones de euros
Corporativa (CFR) de Moody's (de B3 con perspectiva positiva a B2 con perspectiva estable) y una mejora en la Calificación de Incumplimiento del Emisor (IDR) de Fitch Ratings (de B con perspectiva positiva a B+ con perspectiva estable), mientras que Standard & Poor's ratificó la Calificación Crediticia
More news about: FIS
Feb 05, 2026, 11:37 ET FIS CONCLUT AVEC SUCCÈS L'ÉMISSION D'OBLIGATIONS POUR UN MONTANT DE 770 MILLIONS D'EUROS
Family Rating (CFR) (de B3 avec perspectives positives à B2 avec perspectives stables) et de Fitch Ratings un relèvement de l'Issuer Default Rating (IDR) (de B avec perspectives positives à B+ avec perspectives stables), tandis que Standard and Poor's a confirmé la note de crédit de l'émetteur (ICR) de
More news about: FIS
Feb 05, 2026, 10:03 ET FIS SCHLIESST ANLEIHEEMISSION IN HÖHE VON 770 MILLIONEN EURO ERFOLGREICH AB
erhielt FIS ein Corporate Family Rating (CFR) von Moody's (von B3 mit positivem Ausblick auf B2 mit stabilem Ausblick) und ein Issuer Default Rating (IDR) von Fitch Ratings (von B mit positivem Ausblick auf B+ mit stabilem Ausblick), während Standard and Poor's das Issuer Credit Rating (ICR) von B mit
More news about: FIS
Feb 05, 2026, 09:09 ET FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE
received a Corporate Family Rating (CFR) upgrade from Moody's (rating from B3 with positive outlook to B2 with stable outlook) and Issuer Default Rating (IDR) upgrade from Fitch Ratings (from B with positive outlook to B+ with stable outlook), while Standard and Poor's affirmed the Issuer Credit Rating (ICR)
More news about: FIS
Feb 05, 2026, 09:04 ET FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE
received a Corporate Family Rating (CFR) upgrade from Moody's (rating from B3 with positive outlook to B2 with stable outlook) and Issuer Default Rating (IDR) upgrade from Fitch Ratings (from B with positive outlook to B+ with stable outlook), while Standard and Poor's affirmed the Issuer Credit Rating (ICR)
More news about: FIS
Feb 04, 2026, 23:06 ET Wonderful Indonesia Showcase के माध्यम से इंडोनेशिया ने OTM Mumbai और Chennai Sales Mission में अपने बढ़ते भारतीय पर्यटन बाजार को लक्षित किया
पर्यटन हितधारकों को प्रस्तुत करेगा।उन्होंने कहा, "इस वर्ष, हमारा IDR 48 बिलियन के संभावित सौदों और अनुमानित 40,000 भारतीय पर्यटकों के आगमन का लक्ष्य है।"मंत्रालय ने आखिरी बार 2024 में OTM में भाग लिया था, जिससे लगभग IDR 40.7 बिलियन के संभावित सौदे हुए थे। 2025 में, इसने SATTE और ITB India
More news about: The Ministry of Tourism of the Republic of Indonesia